UPMC Hillman Cancer Center | Strategic Alliance Partners

October 18, 2018

Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses EGFR-targeted therapies in non–small cell lung cancer.

August 07, 2018

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses the treatment of pediatric patients with sarcoma.

July 13, 2018

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses clinical needs in pediatric patients with bone sarcoma.

June 29, 2018

Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses PD-L1 expression in lung cancer.

June 21, 2018

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab (Opdivo) in the treatment of patients with head and neck cancer.

April 25, 2018

Robert L. Ferris, MD, PhD, discusses the implications of the updated findings from the phase III CheckMate-141 trial in squamous cell carcinoma of the head and neck.

April 18, 2018

Adjuvant treatment of patients with intermediate- and high-risk melanoma has changed drastically in the past decade, according to John M. Kirkwood, MD.

April 09, 2018

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses the development and approval of biosimilars in oncology.

November 14, 2017

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

July 14, 2015

OncLive® and UPMC CancerCenter, partner with University of Pittsburgh Cancer Institute, have teamed up under OncLive's Strategic Alliance Partnership program.

June 25, 2015

James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.

April 03, 2015

In an interview with OncLive, Nancy E. Davidson discusses her leadership plans for the AACR, as well as precision medicine in oncology®, challenges with research funding, and the role of epigenetics in breast cancer.

March 17, 2015

In an interview with OncLive, Ahmad A. Tarhini, MD, PhD, discussed the benefits and challenges of ipilimumab and other immunotherapies and how they could change the adjuvant treatment paradigm for melanoma.

September 10, 2014

Data from a brand new survey addressed some of the emotional issues faced by physicians when treating and delivering a diagnosis of advanced breast cancer.

August 21, 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.

August 11, 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.

July 11, 2014

Adam M. Brufsky, MD, PhD, discusses the effect of prior trastuzumab on eribulin mesylate in combination with trastuzumab as first-line treatment for HER2-positive locally recurrent or metastatic breast cancer.

April 19, 2013

Patients with epithelial ovarian cancer (EOC) and low levels of the BRCA1 protein had significantly improved overall survival (OS) when their platinum-based chemotherapy was delivered abdominally by injection

July 03, 2012

The administration of nab-paclitaxel plus carboplatin results in a significantly higher ORR than conventional solvent-based paclitaxel with carboplatin in previously untreated patients with advanced NSCLC.